DMARDs may be used for selected autoimmune and inflammatory diseases when inflammation contributes to joint pain, stiffness, enthesitis, or systemic symptoms.
Learn how Dr. Aranguren explains disease-modifying antirheumatic drugs (DMARDs), how they help manage inflammatory conditions, and their role in reducing pain and preventing joint damage.
Our team organizes conditions and treatments into related zones of expertise to make it easier to explore the care paths most relevant to your symptoms and goals.
Use the zone tags above to browse dedicated pages for each focus area, including services, providers, and what to expect during treatment.
If you’ve been diagnosed with an autoimmune or inflammatory condition, you may have heard the term DMARDs and wondered what that actually means. DMARD stands for Disease-Modifying Anti-Rheumatic Drug.
These medications are used to treat conditions like rheumatoid arthritis, psoriatic arthritis, lupus, and other inflammatory disorders by helping calm the immune system and reduce ongoing inflammation.
What makes DMARDs different from simple pain medications is that they’re not just masking symptoms temporarily. The goal is to actually slow down the inflammatory process that can lead to joint damage, stiffness, swelling, fatigue, and long-term complications over time.
When autoimmune inflammation stays active, it can affect the joints, muscles, connective tissues, and even the nervous system. That’s why early treatment and good inflammation control are so important.
Some DMARDs are traditional medications like methotrexate or hydroxychloroquine, while others may be newer targeted therapies or biologic medications depending on the condition and severity.
My approach is always individualized. We look at symptoms, lab work, imaging, disease activity, and the patient’s overall health to determine which treatment strategy makes the most sense. These medications do require monitoring, but for many patients they can significantly improve quality of life, reduce flares, and help protect the body from ongoing inflammatory damage.
If you’ve been struggling with autoimmune symptoms, joint pain, stiffness, swelling, or inflammatory flare-ups, DMARD therapy may be an important part of building a long-term treatment plan that addresses the root inflammatory process, not just the pain itself.
DMARDs, or disease-modifying antirheumatic drugs, are medications used for selected autoimmune and inflammatory diseases. They are not general pain relievers. Instead, DMARDs are designed to help reduce inflammatory disease activity over time in conditions such as rheumatoid arthritis, psoriatic arthritis, lupus, Sjogren’s, vasculitis, seronegative spondyloarthropathy, and other inflammatory conditions when clinically appropriate.
At Manhattan Pain Medicine, DMARDs treatment NYC care is approached through diagnosis-first pain evaluation, inflammatory pain recognition, medication safety awareness, and coordination with rheumatology or other specialists when needed.
MPM specialists evaluate whether pain appears inflammatory, autoimmune, mechanical, neuropathic, centralized, or mixed. This matters because DMARDs may help reduce disease activity in selected inflammatory conditions, but they are not designed to treat every pain pattern. A patient with rheumatoid arthritis, psoriatic arthritis, lupus, Sjogren’s, vasculitis, enthesitis, or seronegative spondyloarthropathy may need rheumatology-coordinated medication planning.
MPM also considers whether persistent pain may be related to spine disease, joint damage, nerve irritation, gout, hypermobility, tendinopathy, or central sensitization, even when autoimmune disease is already being treated.
DMARDs work differently from NSAIDs, steroids, opioids, and many other pain medications. They are intended to reduce inflammatory disease activity rather than provide immediate pain relief. Depending on the diagnosis, DMARDs may help protect joints, reduce inflammation, and slow disease progression over time.
There are different categories of DMARDs, including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs. The right choice depends on the condition being treated, disease severity, prior response, side effects, safety factors, monitoring requirements, cost, and patient preferences. MPM does not present DMARDs as standalone pain medication or prescribe them automatically. Instead, MPM helps evaluate whether the patient’s pain pattern suggests inflammatory disease and whether medication coordination with rheumatology, dermatology, gastroenterology, or another specialist may be appropriate. If pain persists despite DMARD treatment, MPM also evaluates mechanical, neuropathic, hypermobility-related, or centralized pain contributors.
DMARDs fit within MPM’s Autoimmune and Inflammatory Zone of Expertise. Many patients with autoimmune or inflammatory disease experience pain from more than one source. Inflammation may affect joints, tendons, entheses, connective tissue, skin, or systemic function. At the same time, patients may also have spine pain, nerve pain, hypermobility-related pain, gout, mechanical joint disease, or central sensitization.
MPM helps evaluate these overlapping patterns so DMARDs are not treated as the entire answer. When DMARDs are appropriate, care is often coordinated with rheumatology, dermatology, gastroenterology, or another specialist. When pain continues despite treatment, MPM helps evaluate whether additional pain generators should be addressed through medication management, biologics, infusions, procedures, rehabilitation, or other coordinated care.
During evaluation, MPM reviews the patient’s diagnosis, symptoms, inflammatory pain features, prior medication history, lab results, imaging, specialist involvement, and treatment response. Patients may be asked about morning stiffness, swelling, flares, rashes, psoriasis, tendon or enthesis pain, joint warmth, fatigue, spine or SI joint symptoms, and whether symptoms improve or worsen with activity.
If DMARDs may be relevant, MPM may coordinate with rheumatology or another specialist for medication selection and monitoring. DMARDs may require liver and kidney function review, blood count monitoring, infection risk review, vaccine review, medication interaction review, alcohol use review for some agents, pregnancy considerations, and ongoing follow-up. The plan depends on the diagnosis, medication, safety profile, and care team.
I cannot say enough good things about Manhattan Pain Medicine. From the moment I walked in, I felt truly cared for and taken seriously. Dr. Nino Mikaberidze, Director of Rheumatology, is exceptional — knowledgeable, compassionate, and incredibly thorough. She takes the time to listen, explains every...
The best care I've received as a chronic pain patient. I traveled from out of state to visit Manhattan Pain Medicine because I could not find knowledgeable doctors in my hometown for my hypermobility, and Ehlers-Danlos syndrome symptoms and comorbidities. Let me tell you, it was worth every travel e...
I was injured in a bicycle accident over 8 years ago. I’ve suffered throughout the years since my accident with nothing seeming to work. PT, Yoga, lifestyle changes, NOTHNG! I finally made an appointment with Dr Kane and I’m feeling an improvement in my life. I no longer stay up all night in pain, a...
One of the best experiences, if not the best, I have ever had at the doctor’s office. From the front desk to the nurses to the PA assisting the doctor this was a great experience. Dr.Nino actually listened to me and came up with a game plan. Would recommend this practice to as many people as I could...
I have very unique & severe nerve pain from CRPS which has no known specific cure. Dr. Siefferman has a huge tool box, far greater than the other 23 Drs. I have seen. He saved me from jumping off a bridge and continues to help me with both treatments and advice. Dr. S. is in a different league!
After two years of searching and feeling lost and let down, I finally found real help at Manhattan Pain Medicine. With Dr. Siefferman, Adam Rosenberg, Dr. Mikaberidze, and the whole team, I feel heard, supported and understood. Every symptom is being considered and I’m finally getting answers with m...
Why is Dr Dr. Tayyaba Ahmed one of the top pevic Floor specialists - 1- She wants to know a full history of what led the patient to get to this point. 2 - She listens intensley to the patient 3- She does not rush you 4- Extremely skilled at giving pelvic floor injections 5- I thank my luck stars she...
The staff was friendly and helpful. Dr. Siefferman was thoughtful, listened, asked questions and proposed simple safe ways to come to further conclusions regarding my pain and discomfort. The office staff including Dr. Siefferman is responsive even after the initial in-person visit. Very pleased.
Dr. Siefferman is a brilliant provider. While my pain is still a work in progress, Dr Siefferman always gives me options and explains his reasoning behind things. He listens to my feedback and concerns. I never feel rushed; and am grateful he works to meet me where I am. I highly recommend him.
What a great find! They listen to me, I listen to them and the diagnosis is made and a plan developed to develop an approach to treat all of my chronic pain. I wish I could have discovered this type of treatment sooner. This doctor and group give me hope.
DMARDs are disease-modifying antirheumatic drugs used for selected autoimmune and inflammatory diseases. They are intended to reduce inflammatory disease activity over time rather than simply mask pain. DMARDs may be used in conditions such as rheumatoid arthritis, psoriatic arthritis, lupus, Sjogren’s, vasculitis, seronegative spondyloarthropathy, and other inflammatory conditions when clinically appropriate. At MPM, DMARDs medication management NYC care is approached through diagnosis-first evaluation and coordination with rheumatology or other specialists when needed.
DMARD stands for disease-modifying antirheumatic drug. The term refers to medications that can help modify the course of certain inflammatory or autoimmune diseases. Some DMARDs are conventional synthetic medications, while others are biologic or targeted synthetic medications. The right medication depends on the specific diagnosis, disease activity, prior treatment response, safety profile, and specialist guidance. DMARDs are not automatically appropriate for every patient with joint pain or chronic pain.
DMARDs are not regular pain medications. They are disease-modifying medications used for certain autoimmune and inflammatory diseases. When inflammation is driving symptoms, DMARDs may reduce disease activity and may improve pain, stiffness, swelling, or function over time. They do not provide immediate pain relief like some anti-inflammatory or analgesic medications. Pain may also persist if there are mechanical, neuropathic, hypermobility-related, gout-related, or centralized contributors. MPM evaluates these overlapping possibilities during care planning.
NSAIDs and steroids may reduce inflammation or pain symptoms more directly, but they do not modify autoimmune disease activity in the same way DMARDs can. DMARDs are used to help control specific inflammatory diseases over time. NSAIDs, steroids, and DMARDs each carry different risks and monitoring needs. Some patients may use more than one medication class under specialist guidance. MPM helps evaluate whether symptoms are inflammatory and whether medication coordination with rheumatology may be needed.
Biologics are often considered a type of DMARD, but they differ from traditional conventional synthetic DMARDs. Conventional DMARDs, biologic DMARDs, and targeted synthetic DMARDs work through different mechanisms and have different safety considerations. Biologics often target specific immune pathways and may be given by injection or infusion. The choice depends on diagnosis, severity, prior response, risks, monitoring needs, cost, and specialist guidance. MPM coordinates care when inflammatory pain and medication decisions overlap.
DMARDs may be used for selected autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, lupus, Sjogren’s, vasculitis, seronegative spondyloarthropathy, and other connective tissue or inflammatory diseases. Treatment depends on the specific diagnosis and disease activity. Some symptoms may suggest inflammation even when labs are not definitive, but diagnosis still requires careful evaluation. MPM helps identify inflammatory pain patterns and coordinates with rheumatology or other specialists when DMARD therapy may be relevant.
DMARDs are central to many rheumatoid arthritis treatment plans because they may reduce inflammatory disease activity and help protect joints over time. As inflammation improves, joint pain, swelling, stiffness, and function may improve for selected patients. DMARDs do not cure rheumatoid arthritis and may not resolve pain from joint damage, nerve pain, spine disease, gout, or central sensitization. MPM may coordinate with rheumatology while evaluating other pain generators that may need separate treatment.
DMARDs may be used for selected patients with psoriatic arthritis, psoriasis-related joint pain, or inflammatory enthesitis depending on the disease pattern and specialist recommendation. Enthesitis involves inflammation where tendons or ligaments attach to bone. However, attachment-site pain can also come from mechanical strain, tendinopathy, hypermobility, or injury. MPM evaluates whether symptoms appear inflammatory or mechanical and may coordinate with rheumatology or dermatology when psoriatic arthritis or enthesitis is suspected.
DMARDs or other immune-directed medications may be used in selected cases of lupus, Sjogren’s, vasculitis, or connective tissue disease, depending on the condition, organ involvement, symptoms, labs, and specialist guidance. These conditions can cause pain, fatigue, neuropathic symptoms, inflammatory symptoms, and systemic issues that require careful medical evaluation. MPM helps connect pain evaluation with autoimmune care but does not treat DMARDs as routine pain medication or prescribe them automatically.
DMARDs often take time to show benefit. The timeline depends on the medication, diagnosis, disease activity, dose, and individual response. Some patients may need weeks to months before the response is clear. During that time, monitoring is important. Patients should not stop or change DMARDs without clinician guidance. If pain persists despite inflammatory disease treatment, MPM may evaluate whether another pain generator, such as spine pain, nerve pain, tendinopathy, or central sensitization, is contributing.
Monitoring depends on the specific DMARD and patient history. It may include blood counts, liver function, kidney function, infection risk review, medication interaction review, pregnancy considerations, and ongoing safety checks. Some medications may also require vaccine review or alcohol use review. MPM coordinates with rheumatology or the prescribing specialist when DMARDs are part of the patient’s care plan and pain symptoms need broader evaluation.
Some DMARDs can increase infection risk, especially when they affect immune function or are combined with other immune-modulating medications. The level of risk depends on the medication, dose, other medical conditions, and the patient’s immune status. Patients may need infection screening, vaccine review, and instructions about when to contact a clinician. Fever, signs of infection, shortness of breath, severe rash, or rapidly worsening symptoms should be evaluated promptly.
Yes, in some cases DMARDs may be combined with biologics or infusion-based treatments under specialist guidance. Combination therapy depends on the diagnosis, disease activity, prior response, safety profile, infection risk, lab monitoring, and medication interactions. Patients should not combine or change immune-modulating medications without clinician supervision. MPM helps coordinate pain care when DMARDs, biologics, infusions, and persistent pain symptoms overlap.
MPM’s role is to evaluate pain patterns, identify features that may suggest inflammatory disease, clarify overlapping pain generators, and coordinate with rheumatology when DMARD therapy may be relevant. Rheumatology often manages diagnosis, medication selection, disease activity monitoring, and safety labs. MPM may support the broader pain plan by evaluating mechanical, neuropathic, spine, pelvic, or centralized pain contributors that may persist even when inflammatory disease is being treated.
Before care begins, our team helps patients understand the practical side of treatment, including insurance verification, out-of-network benefits, cost-share estimates, self-pay options, and billing questions. We believe patients should have as much clarity as possible before moving forward.
DMARDs, or disease-modifying antirheumatic drugs, are medications used to treat selected autoimmune and inflammatory diseases. They are not general pain medications. Their purpose is to reduce inflammatory disease activity over time, which may help protect joints, reduce swelling and stiffness, and improve function for selected patients.
At Manhattan Pain Medicine (MPM), DMARDs treatment NYC care is approached through diagnosis-first evaluation and specialist coordination. The goal is to determine whether pain is truly inflammatory, whether DMARDs may be relevant, and whether other pain generators also need to be addressed.
Regular pain medications may reduce pain signals, inflammation, nerve sensitivity, muscle spasm, or symptom burden. DMARDs are different. They are disease-modifying treatments for specific autoimmune or inflammatory conditions. They may be used for rheumatoid arthritis, psoriatic arthritis, lupus, Sjogren’s, vasculitis, seronegative spondyloarthropathy, and other inflammatory conditions when clinically appropriate.
DMARDs may take weeks or months to work, and they require monitoring. They are not usually used simply because a patient has pain. MPM helps evaluate whether the patient’s symptoms suggest inflammatory disease or whether pain may be mechanical, neuropathic, hypermobility-related, gout-related, centralized, or mixed.
DMARD categories include conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs. Conventional synthetic DMARDs may be used in conditions such as rheumatoid arthritis and other inflammatory diseases. Biologic DMARDs target specific immune pathways and may be given by injection or infusion. Targeted synthetic DMARDs work through specific intracellular pathways and require careful monitoring.
The choice of medication depends on diagnosis, disease activity, prior treatment response, risks, side effects, cost, patient preferences, and specialist guidance. MPM does not replace rheumatology management. Instead, MPM helps connect inflammatory disease treatment with pain generator evaluation and coordinated care.
DMARDs may be relevant when pain is linked to inflammatory arthritis, joint swelling, prolonged morning stiffness, psoriasis-related joint symptoms, inflammatory enthesitis, lupus-related symptoms, Sjogren’s overlap, vasculitis, or connective tissue disease. For example, a patient with hand swelling and stiffness may need evaluation for rheumatoid arthritis. A patient with psoriasis and tendon insertion pain may need assessment for psoriatic arthritis or enthesitis. A patient with widespread autoimmune symptoms may need broader specialist evaluation before medication decisions are made.
However, these symptoms are not always inflammatory. Joint pain can come from osteoarthritis, gout, injury, overuse, instability, nerve irritation, or spine referral. SI joint pain can be inflammatory or mechanical. Tendon pain can be enthesitis or tendinopathy. MPM evaluates these possibilities before assuming that DMARDs are the right pathway.
Some patients continue to have pain even when autoimmune disease is being treated. This does not mean the pain is not real. It may mean that another pain generator is present. Persistent pain may come from joint damage, tendinopathy, nerve irritation, small fiber neuropathy, spine disease, sacroiliac joint dysfunction, hypermobility, gout, central sensitization, or deconditioning.
MPM helps evaluate these overlapping contributors. A patient may need imaging review, diagnostic ultrasound, targeted injections, medication management, biologics, infusions, rehabilitation, or additional specialist coordination. DMARDs may reduce inflammatory disease activity, but they may not resolve pain from mechanical, neuropathic, hypermobility-related, or centralized sources.
DMARDs require careful safety review. Depending on the medication, patients may need blood count monitoring, liver function monitoring, kidney function monitoring, infection risk review, vaccine review, pregnancy considerations, alcohol use review for some medications, and medication interaction review. Some patients may need coordination with rheumatology, dermatology, gastroenterology, primary care, or another clinician.
Patients should report fever, signs of infection, shortness of breath, chest pain, severe allergic reaction, severe rash, mouth sores, unusual bruising or bleeding, yellowing of the skin or eyes, severe abdominal pain, black or bloody stool, new neurological symptoms, rapidly worsening weakness, or rapidly worsening symptoms.
For selected patients, DMARDs may be an important part of autoimmune and inflammatory pain care. MPM’s role is to help determine whether inflammation is likely contributing to symptoms, whether DMARD-related care should be coordinated, and whether additional pain sources need targeted evaluation.
